Tidal Investments LLC Grows Stake in Becton, Dickinson and Company (NYSE:BDX)

Tidal Investments LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 309.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 47,461 shares of the medical instruments supplier's stock after purchasing an additional 35,858 shares during the quarter. Tidal Investments LLC's holdings in Becton, Dickinson and Company were worth $11,443,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB increased its position in Becton, Dickinson and Company by 93.8% in the third quarter. Wilmington Savings Fund Society FSB now owns 151,082 shares of the medical instruments supplier's stock worth $36,426,000 after buying an additional 73,108 shares in the last quarter. World Investment Advisors LLC increased its holdings in Becton, Dickinson and Company by 36.3% in the 3rd quarter. World Investment Advisors LLC now owns 13,943 shares of the medical instruments supplier's stock worth $3,362,000 after acquiring an additional 3,713 shares in the last quarter. Anchor Investment Management LLC raised its stake in Becton, Dickinson and Company by 8.3% during the 3rd quarter. Anchor Investment Management LLC now owns 940 shares of the medical instruments supplier's stock worth $227,000 after acquiring an additional 72 shares during the period. M&T Bank Corp lifted its holdings in Becton, Dickinson and Company by 1.9% during the third quarter. M&T Bank Corp now owns 53,102 shares of the medical instruments supplier's stock valued at $12,803,000 after purchasing an additional 996 shares in the last quarter. Finally, Virtue Capital Management LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter worth approximately $339,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded down $1.17 during midday trading on Friday, reaching $226.00. 1,725,792 shares of the stock traded hands, compared to its average volume of 1,455,104. The stock has a market cap of $65.34 billion, a P/E ratio of 38.24, a PEG ratio of 1.64 and a beta of 0.41. The stock's fifty day moving average is $231.25 and its 200-day moving average is $233.36. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same quarter in the previous year, the business posted $3.42 earnings per share. Becton, Dickinson and Company's quarterly revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a $1.04 dividend. This is an increase from Becton, Dickinson and Company's previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.84%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 70.03%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 638 shares of the firm's stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the sale, the executive vice president now owns 14,217 shares of the company's stock, valued at $3,113,949.51. This trade represents a 4.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.31% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of analyst reports. Citigroup upgraded shares of Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and lifted their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI upped their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $283.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.